Plasma levels of sulfinpyrazone and of two of its metabolites after a single dose and during the steady state.
The pharmacokinetics of sulfinpyrazone, and the plasma levels of its sulfide and sulfone metabolites, have been determined after a single oral dose (400 mg) and during steady-state conditions (4 x 200 mg daily for 6 days) in healthy female volunteers. The plasma half-lives of sulfinpyrazone, the sulfone and the sulfide were 3.7, 3.2 and 14.7 h, respectively, during steady-state. After a single dose and during steady state conditions the half-lives of sulfinpyrazone and the sulfone did not differ significantly. The trough plasma levels of the sulfide metabolite exceeded those of the parent compound in four of the six volunteers on the last day of the study. The data suggest that in man the most likely candidate for the prolonged inhibition of platelet aggregation observed after treatment with sulfinpyrazone is its sulfide metabolite, because of its prolonged elimination.
D000328:Adult; D005260:Female; D006207:Half-Life; D006801:Humans; D010974:Platelet Aggregation / Q000187:drug effects; D013440:Sulfides / Q000378:metabolism; D013442:Sulfinpyrazone / Q000008:administration & dosage / Q000097:blood / Q000378:metabolism*
D013440:Sulfides; D013442:Sulfinpyrazone